Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme—improvement over available therapy?

Sajeel Chowdhary and Eric T Wong*

Correspondence *Brain Tumor Center and Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA

Email ewong@bidmc.harvard.edu

This article has no abstract so we have provided the first paragraph of the full text.

Classic neuroscience teaching divides the brain into neurons and glia, but it is increasingly clear that the extracellular environment, or stroma, has a pivotal role in neurodevelopment and disease. The importance of stroma as a target of anticancer therapy has come to light in the era of antiangiogenic drugs. In a phase II trial, Vredenburgh et al.

Full text of this article is available with one of the following:

- Personal subscription
  - Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18
  - In order to purchase this article you must be a registered user. Please register or log in.
- Site licence
  - Learn more about institutional site licences

Please log in to access the full text article using the login box at the top of the page.